Form 4: Myomo CEO Paul Gudonis Receives 130,000 Restricted Stock Units

Myomo CEO Paul Gudonis was granted 130,000 restricted stock units (RSUs) on June 5, 2024, which vest annually over three years starting June 5, 2025.

Summary

• Paul R. Gudonis, CEO of Myomo, Inc., received 130,000 restricted stock units on June 5, 2024.
• These RSUs vest in annual installments over three years, beginning on June 5, 2025.
• Following this transaction, Gudonis directly owns 959,845 shares of Myomo common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The RSU grant is a standard practice and indicates confidence in the CEO's ability to drive future growth, but it also carries a risk of dilution.

Positives

• The grant of RSUs to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance over the vesting period.

Risks

• The vesting of the RSUs could potentially dilute existing shareholders' equity over the next three years.

Future Outlook

The document does not contain specific forward-looking statements, but the RSU grant suggests a continued commitment to incentivizing the CEO's performance over the next three years.

Industry Context

Grants of restricted stock units are a common practice in the industry to align management's interests with those of shareholders and incentivize long-term performance.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in publicly traded companies, particularly in growth-oriented sectors like medical technology.
• The size of the grant should be compared to grants made to executives at comparable companies in the medical device industry to assess its relative value and potential impact on shareholder dilution.

Stakeholder Impact

• Shareholders may experience potential dilution over the vesting period.
• Employees may view the RSU grant as a positive sign of the company's commitment to its leadership.

Key Dates